Effects of cyclosporine A and methotrexate on CD18 expression in recipients of rat cardiac allografts

• Published in: Transplant immunology Vol. 6; no. 2; pp. 122 - 133
• Main Authors: Ciesielski, Cathleen J, Mei, Jia, Piccinini, Linda A
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.06.1998
• Subjects: Animals; CD18 Antigens - biosynthesis; Cyclosporine - pharmacology; Gene Expression - drug effects; Graft Rejection - drug therapy; Graft Rejection - metabolism; Graft Rejection - pathology; Heart Transplantation - immunology; Immunohistochemistry; Immunosuppressive Agents - pharmacology; Leukocytes - immunology; Methotrexate - pharmacology; Myocardium - metabolism; Rats; Rats, Inbred BN; Rats, Inbred Lew; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterotopic - immunology
• DOI: 10.1016/S0966-3274(98)80027-0
• ISSN: 0966-3274

Recent advances in the study of the molecular basis of inflammation suggest that cell-cell interactions mediated by specific adhesion molecules could be new targets for immunosuppression. Methotrexate (MTX)-treated cells in vitro have demonstrated decreased neutrophil-endothelial cell adhesion associated with increased release of adenosine from endothelial cells, while the direct role of cyclosporine A (CSA) in the regulation of cell adhesion molecule (CAM) expression is less well-defined. Since the adhesion of leucocytes to endothelial cells via CAMs is necessary for leucocyte extravasation and infiltration into graft tissue during allograft rejection, these studies have addressed the hypothesis that MTX treatment of cardiac transplant recipients may affect cellular adherence by downregulating cell adhesion molecule expression. Using a vascularized method of rat cardiac transplantation, our studies have previously demonstrated that low doses of the immunosuppressive agents CSA and MTX, when used in combination, significantly increase allograft survival. According to reverse transcriptase-polymerase chain reaction (RT-PCR) methodology to measure changes in steady-state CD18 mRNA levels, and immunohistochemistry to assess transplant CD18 protein levels in situ, both CD18 transcript and protein levels were significantly increased in untreated allografts when compared to isograft tissues on days 3 through to 7 post-transplant. Whereas, both low-dose CSA alone and low-dose MTX alone treatment resulted in similar levels of graft leucocyte infiltration, MTX-treated recipients demonstrated lower levels of CD18 expression when compared to low-dose CSA alone treatment. The results of immunohistochemical staining for T cells, where significantly fewer T cells were observed in rat cardiac allografts after low-dose MTX treatment alone compared to low-dose CSA treatment, were noteworthy. Results of these studies indicate that CD18 expression and infiltrating T cell numbers in Brown Norway (BN) to Lewis (Lew) rat cardiac allografts are significantly diminished with low-dose MTX treatment. The immunosuppressive effects of MTX, therefore, may be related to its ability to interfere with an early step during the cell-mediated immune response, namely the firm binding or ‘adhesion’ of leucocytes to the endothelium during transendothelial migration.